Contains Insights Into Enabling Technologies such as Peptide Hydrogel Technology for Cell Culture and Microfluidic Bioprocessing, as Well as Diagnostics for COVID-19, Neurodegenerative Disorders and Mental Health
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) consists of insights across phosphoproteome and ultrasound-based drug-discovery, drug nanoformulations, drugs for antimicrobial resistance, immunotherapy for autoimmune diseases, gene therapy for phenylketonuria. Further, it contains enabling technologies such as peptide hydrogel technology for cell culture, microfluidic bioprocessing, nano biopolymer-based fluorescent dyes for therapeutic imaging, neuroimaging technologies as well as diagnostic for COVID-19, neurodegenerative disorders and mental health.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
1. Innovations in Life Sciences, Health & Wellness
- Kinomica Ltd. UK - Growth Opportunities
- Infex Therapeutics, UK - Growth Opportunities
- Manchester Biogel, UK - Growth Opportunities
- Blueberry Therapeutics, UK - Growth Opportunities
- Stream Bio Ltd. UK - Growth Opportunities
- Mirobio, UK - Growth Opportunities
- Oxsonics Therapeutics Ltd. UK - Growth Opportunities
- Oxford Vacmedix UK Limited, UK - Growth Opportunities
- Erbi Biosystems, US - Growth Opportunities
- Transgene SA, France - Growth Opportunities
- University College London, UK - Growth Opportunities
- University of Washington School of Medicine, US - Growth Opportunities
- Braintale, France - Growth Opportunities
- Homology Medicines, US - Growth Opportunities
- Nanobiotix SA, France - Growth Opportunities
- Karolinska Institute, Sweden - Growth Opportunities
- Breathonix, Singapore - Growth Opportunities
- Psyomics, UK - Growth Opportunities
- Stanford University, US - Growth Opportunities
- Cellcentric Ltd. UK - Growth Opportunities
- Sight Diagnostics, Israel - Growth Opportunities
- Yumanity, US - Growth Opportunities
- Alector, US - Growth Opportunities
- C2N Diagnostics, US - Growth Opportunities
- Genomtec, US - Growth Opportunities
- Predictimmune Ltd. UK - Growth Opportunities
2. Key Contacts
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alector
- Blueberry Therapeutics
- Braintale
- Breathonix
- C2N Diagnostics
- Cellcentric Ltd.
- Erbi Biosystems
- Genomtec
- Homology Medicines
- Infex Therapeutics
- Karolinska Institute
- Kinomica Ltd.
- Manchester Biogel
- Mirobio
- Nanobiotix SA
- Oxford Vacmedix UK Limited
- Oxsonics Therapeutics Ltd.
- Predictimmune Ltd.
- Psyomics
- Sight Diagnostics
- Stanford University
- Stream Bio Ltd.
- Transgene SA
- University College London
- University of Washington School of Medicine
- Yumanity
